Impact of fibrinogen-to-albumin ratio on the long-term prognosis of patients with advanced HER2-negative gastric cancer receiving immunochemotherapy

doi:10.4251/wjgo.v17.i6.107980

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 6

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (305)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-6) series, Tables (1-6) series.

Item

Count

PDF

HTML

135

Figures (1-6)

Tables (1-6)

Sum=233

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=60

Jun 15, 2025 (publication date) through Jun 19, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastrointest Oncol. Jun 15, 2025; 17(6): 107980
Published online Jun 15, 2025. doi: 10.4251/wjgo.v17.i6.107980

Full Size Figure Download Figure

Figure 1 Flow chart of the screening process for advanced gastric cancer patients receiving immunotherapy combined with chemotherapy. PD-1: Programmed cell death protein 1; PD-L1: Programmed cell death ligand 1; FAR: Fibrinogen-to-albumin ratio.

Citation: Yao ZY, Liu J, Ma X, Li WT, Shen Y, Cui YZ, Fang Y, Han ZX, Yang CH. Impact of fibrinogen-to-albumin ratio on the long-term prognosis of patients with advanced HER2-negative gastric cancer receiving immunochemotherapy. World J Gastrointest Oncol 2025; 17(6): 107980
URL: https://www.wjgnet.com/1948-5204/full/v17/i6/107980.htm
DOI: https://dx.doi.org/10.4251/wjgo.v17.i6.107980